Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Nab-paclitaxel and gemcitabine combating pancreatic cancer

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.12
Views: 5020

Dr Michel Ducreux – Institut Gustave Roussy, Paris, France

Dr Michel Ducreux talks to ecancer at ESMO 2012 in Vienna about emerging therapies for pancreatic cancer.


The prognosis for pancreatic cancer is often very poor with overall survival averaging 6 months with metastasis.


Dr Ducreux discuss on going trials that are testing the new compounds nab-paclitaxel and gemcitabine against the standard treatments. In addition the compund TH302, which fights against the cells even with hypoxia, was tested in comination with gemcitabine.


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation